合肥市创业投资引导基金投资企业轩竹生物成功登陆港交所

Core Viewpoint - XuanZhu Biotechnology Co., Ltd. successfully listed on the Hong Kong Stock Exchange, with an initial offering price of HKD 11.60 per share and a first trading price of HKD 29.46, reflecting a significant increase of 153.97% [1] Group 1: Company Overview - XuanZhu Biotechnology, established in 2018, is a China-based biopharmaceutical company focused on improving patient health and quality of life through innovation [2] - The company has a strong internal R&D platform and targets major diseases such as digestive system diseases, tumors, and non-alcoholic fatty liver disease (NASH) [2] - XuanZhu has developed a pipeline of innovative drugs at various clinical stages, with over ten drug assets in development [2] Group 2: Product Development - The company has three core products that have received NDA approval: an innovative proton pump inhibitor KBP-3571 for digestive system diseases, a CDK4/6 inhibitor XZP-3287 for breast cancer, and an ALK inhibitor XZP-3621 for non-small cell lung cancer (NSCLC) [3] - XuanZhu has adopted a dual-track model of "independent R&D + external licensing" to accelerate drug commercialization, having obtained 20 IND approvals and submitted or received approval for 7 NDAs [3] - The strategic collaboration with its controlling shareholder, SiLian Pharmaceutical Holdings Group Co., Ltd., has enabled XuanZhu to establish a complete value chain system covering drug discovery, clinical development, and commercialization [3]